It has been reported that Stat5 is overexpressed in a variety of human cancer cell lines and primary tumors. Inhibition of Stat5 in tumor cell lines has been associated with growth suppression and induction of apoptosis. However, no one of published studies have investigated the expression and role of Stat5 in hepatocellular carcinoma. In this study, we used human hepatocellular carcinoma cell line SMMC7721 as a model to demonstrate that Stat5 was highly expressed in these cells. Next we showed that RNAi mediated Stat5 knockdown could inhibit the proliferation and induce the apoptosis of SMMC7721 cells in vitro. Furthermore, we demonstrated that Stat5 knockdown inhibited the growth and induced the apoptosis of SMMC7721 cells in xenografts in nude mice. Taken together, our in vitro and in vivo data suggest that Stat5 plays an important role in human hepatocellular carcinoma. Inhibition of Stat5 by RNAi holds promise to be a novel gene therapy vector for hepatocellular carcinoma.
The signal transducers and activators of transcription (Stat) factors are the key effectors of signaling downstream of cytokine and growth factor receptors. Stat is one of the family of cytoplasmic transcription factors that transmit the signals, usually generated at cell surface, to the nucleus where Stat binds to specific DNA promoter sequences and consequently regulate gene expression. Seven different Stat (Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6) encoded by distinct genes have been identified in mammalian cells [1] . Accumulating evidence suggests that Stat5, a typical member of Stat family, functions as a survival protein in a number of normal and malignant cells of hematopoietic origin [2] . Constitutive activation of Stat5 is known to be present in a variety of blood-derived malignancies including chronic myelogenous leukemia (CML). Inhibition of Stat5 activation in tumor cell lines has been associated with growth suppression and induction of apoptosis [3, 4] . These findings suggest that Stat5 could be a novel molecular target for therapeutic intervention in human cancer [5] .
However, the expression and role of Stat5 in hepatocellular carcinoma cells remain largely unknown. We hypothesized that Stat5 may play a role in the regulation of proliferation and apoptosis in cancer cells of hepatocellular carcinoma. Therefore, we employed hepatocellular carcinoma cell line SMMC7721 as a model, which was established from a Chinese male patient with hepatocellular carcinoma. This study was designed to examine the expression of Stat5 protein in SMMC7721 cells and further investigate the role of Stat5 in the tumorigenesis of hepatocellular carcinoma by in vitro cell study and in vivo xenograft study in nude mice.
Materials and methods
Cell culture. Cell lines SMMC7721, K562, mouse ascites hepatomas cell line H22 and murine mammary carcinomas cell line HA8911 were obtained from the Research Center of the Fourth Hospital of Hebei Medical University, and cultured in RPMI-1640 medium supplemented with 2 mmol/L Glutamax, 100 U/ml penicillin, 100 μg/ml streptomycin, 10 mmol/l HEPES (Invitrogen, Carlsbad, USA) and 10% FCS (Sijiqing, Hangzhou, China). Cell lines were maintained in a 5% CO2 incubator at 37°C and passaged using trypsin/EDTA (Invitrogen, Carlsbad, USA).
Construction of RNA interference vector targeting Stat5. Stat5 is encoded by two highly homologous genes Stat5a and Stat5b [6] . Therefore, three small interference RNA (siRNA) sequences targeting the shared part of both the Stat5a and Stat5b genes (NM_003152.2 and NM_012448.3) were designed to inhibit these two genes simultaneously. The three siRNA oligonucleotide sequences were as follows: 1. ATGCCATT-GACTTGGACAA; 2. GATCAAGCTGGGGCACTAC; and 3. CCTGGATGAGACCATGGAT. The Stat5 short hairpin RNA (Stat5 shRNA) template sequence structure was as follows: BamHI+ Sense + Loop+ Antisense + terminal signal + SalI+HindIII. The designed oligos were synthesized by GeneSil Biotechnology (Wuhan, China). The three specific recombinant plasmid vectors were constructed and named Pgenesil-1-Stat5A1, Pgenesil-1-Stat5A2, and Pgenesil-1-Stat5A3, respectively. Plasmid expressing irrelevant shRNA with a random combination was used as negative control and named Pgenesil-1-HK. All the recombinant vectors were confirmed by DNA sequencing analysis.
Transfection. SMMC7721 cells in the exponential phase of growth were plated in 6-well plates at 2x10 5 Semi-quantitative PCR. Total RNA was extracted from cells and tissues using Trizol (Gibco, Gaithersburg, USA). Reverse transcription (RT) was performed by RT kit (Takara, Dalian, China) according to the manufacturer's instructions. The forward and reverse primer sequences for Stat5 were as follows: 5GAGTCTCAGTTCAGTGTTGGCAGC3; and 5AGT CACTAAAGCGCAACAAGAAGGTC3. The forward and reverse primer sequences for β-actin were as follows: 5TGAGACCTTC AACACCCCAG3; and 5GCCATCTC TTGCTCGAAGTC3' . Level of Stat5 mRNA expression in the tested samples was normalized to the corresponding β-actin mRNA transcript.
Western blot. Lysate was taken from cells and the protein concentration of the lysate was determined by BCA method, 100µg protein was loaded in each lane and subjected to 8% SDS-PAGE gel electrophoresis, then transferred to nitrocellulose membrane for immunoblotting. The membranes were probed with antibodies against Stat5 or β-actin (Cell Signal, Danvers, USA) overnight at 4°C. Then the membranes were washed with TBST, and incubated for 2 h with HRPconjugated rabbit anti-mouse secondary antibody (Santa Cruz, USA ). Immunoreactive bands were visualized with 3, 3-diaminobenzidine (DAB) (Zhongshan Biotechnology, Beijing, China).
Cell viability assay. Cell proliferation was assessed by MTT (3-(4, 5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) assay as described previously [7] . Briefly, SMMC7721 cells were seeded into a 96-well plate at 2×10 4 cells/well. After incubation for 12 h, the cells were treated with serum-free medium, Pgenesil-1-HK, or Pgenesil-1-Stat5A1, respectively for 8 h. Then the medium was replaced with fresh complete medium and the culture was further incubated for 48 h. Next, the media was carefully removed, and 150 µl serum-free RPMI-1640 medium containing 15µl 5mg/ml MTT (Promega, Madison, USA) was added to each well. Cells were incubated at 37°C for 4 h, then the medium was totally removed and 150µl DMSO (Promega, Madison, USA) was added to each well. The optical absorbance (A) of each well was measured at 570 and 630nm with a microplate reader. The percentage of cell viability was calculated as follows: (A of experimental group/A of control group) ×100%.
Flow cytometry analysis for apoptosis. DNA content was determined by flow cytometry using PI staining (Promega, Madison, USA). Briefly, cells were harvested, washed twice with PBS and fixed in 80% ethanol at 4°C for at least 12h. After being centrifuged, the cells were incubated in PBS containing 200µg/ml DNase-free RNaseA at 37°C for 20 min. Then the cells were incubated in PBS containing 50µg/ml PI for 30min on ice in the dark. For each sample, 3×10 4 cells were analyzed for DNA content using a Coulter EPICS XLTM from Beckman Coulter and CellFit software.
Transmission electron microscopy. Cells were collected, centrifuged at 200g for 10 min and washed twice with PBS. The cells were then fixed with 2.5% glutaraldehyde in PBS at 4°C for 2 h and washed three times in PBS. After being fixed in 1% osmium tetroxide, cells were dehydrated using an ethanol series, embedded in epoxy resin, and cut into ultrathin slices. After being stained with uranium acetate and lead citrate, the slices were observed under a transmission electron microscope (JEM-2100H II, Japan) and electron micrographs were taken.
Xenograft in nude mice. Balb/c-nu/nu mice were obtained from Chinese Academy of Medical Sciences (Beijing) and maintained according to "NIH Guide for the Care and Use of Laboratory Animals". The study was approved by the Ethics Board of Hebei Medical University. SMMC7721 cells were resuspended in serum-free medium at 2×10 7 cells/ml, and 200μl cell suspension was injected into the right flank of each nude mice. The mice were randomly divided into test group and control group when the SMMC7721 tumor cells xenograft was incubated for 15d. Mice in each group were intratumorally injected with 200μl Pgenesil-1-Stat5A1, Pgenesil-1-HK, NS (Blank group) , respectively every 2 days, for a total of 10 injections. The process of tumorigenesis was monitored and the tumor volumes were calculated as (a×b 2 )/2 [8] (a and b represented the long and short axis of the tumor, respectively) every 5 days. On the thirty-fifth day, tumors were harvested.
The tumor inhibition rate was defined as reduced volume of tumor: (tumor volume before injection -tumor volume at the end)/tumor volume before injection.
Statistical analysis. Average values were expressed as mean ± SD. The statistical significance of differences in mean values was assessed by Student's test and A one-way analysis of variance (ANOVO) using SPSS 10.0 statistical software. p < 0.05 was considered statistically significant.
Results

Evaluation of Stat5 knockdown in SMMC7721 cells.
To investigate the role of Stat5 in hepatocellular carcinoma cells, we made Stat5 shRNA constructs to knockdown Stat5 in these cells. After transfection of different Stat5 shRNA constructs into these cells, we detected Stat5 expression by RT-PCR and Western blot analysis. RT-PCR results showed that the integral optical density (IOD) ratio of Stat5 mRNA relative to β-actin in experimental groups (cells without transfection; Pgenesil-1-HK; Pgenesil-1-Stat5A1; Pgenesil-1-Stat5A2; Pgenesil-1-Stat5A3) was 0.976±0.038, 0.973±0.033, 0.288±0.063, 0.555±0.082, and 0.535±0.073, respectively. The inhibition rate of Stat5 mRNA expression among Pgenesil-1-Stat5 shRNA expression vectors (Pgenesil-1-Stat5A1; Pgenesil-1-Stat5A2; Pgenesil-1-Stat5A3) was 70.43%, 43.02%, and 45.07%, respectively (Fig. 1A, B) . Moreover, Western blot results showed that the IOD ratio of Stat5 protein relative to β-actin in experimental groups (cells without transfection; Pgenesil-1-HK; Pgenesil-1-Stat5A1; Pgenesil-1-Stat5A2; Pgenesil-1-Stat5A3) was 0.963±0.042, 0.992±0.053, 0.318±0.072, 0.612±0.065, and 0.568±0.083, respectively. The inhibition rate of Stat5 protein expression among Pgenesil-1-Stat5 shRNA expression vectors (Pgenesil-1-Stat5A1; Pgenesil-1-Stat5A2; Pgenesil-1-Stat5A3) was 67.45%, 37.36%, and 41.86%, respectively (Fig. 1C, D) . These results demonstrated that Stat5 expression at both mRNA and protein levels was significantly decreased in SMMC7721 cells transfected with Stat5 shRNA compared to control group (p < 0.05). Pgenesil-1-Stat5A1 construct was especially effective in silencing Stat5 in SMMC7721 cells and selected for the following experiments.
Stat5 k n o ckd ow n prom otes th e ap opto sis of SMMC7721 cells. SMMC7721 cells were treated with serum-free medium (blank group), Pgenesil-1-HK, or Pgenesil-1-Stat5A1. Cell viability assay showed that the viability of the three groups was 0.711±0.036, 0.715±0.045, and 0.400±0.026, respectively. Stat5 shRNA significantly inhibited the proliferation of SMMC7721 cells (p < 0.05) and the inhibitory rate was 51%. We speculated that the inhibition of cell growth by Stat5 shRNA is due to the induction of apoptosis. Therefore, we performed flow cytometry analysis and found the typical sub-diploid population or sub-G1 peak in SMMC7721 cells treated with Pgenesil-1-Stat5A1 (Fig. 2A) . The amount of apoptotic cells in the group treated with Pgenesil-1-Stat5A1 increased significantly (23.60±1.99%) compared to the untreated group (3.35±1.20%) (p < 0.05, Fig. 2B ). Furthermore, we employed transmission electron microscopy to analyze the ultrastructural changes in SMMC7721 cells transfected with Pgenesil-1-Stat5A1. We observed typical apoptotic features characterized by volume reduction, chromatin condensation, nuclear fragmentation, presence of apoptotic bodies, and cytoplasm vacuolization (Fig. 2C) . Similar induction of apoptosis of SMMC7721 cells was observed using other two shRNA constructs Pgenesil-1-Stat5A2 and Pgenesil-1-Stat5A3 although the effects were not as strong as induced by Pgenesil-1-Stat5A1 (Fig. 3) . When summarizing, these results demonstrated that Stat5 knockdown promotes the apoptosis of SMMC7721 cells.
Stat5 knockdown inhibits the growth of tumor xenograft in nude mice. To investigate the in vivo role of Stat5 in hepatocellular carcinoma, we performed tumor xenograft experiments. The tumor growth curves showed that the tumor derived from SMMC7721 cells in the control groups continued to grow. In contrast, the tumor derived from SMMC7721 cells in the Pgenesil-1-Stat5A1 group grew slowly (Fig. 4A) . On the day 20 after the last injection, we measured the weight and volume of tumor in the three experimental groups. The results showed that the weight and volume of tumor in NS group (3.10±0.25 g and 605±15 mm 3 , respectively) and Pgenesil-1-HK group ( 3.05±0.20g and 595±13 mm 3 , respectively) were significantly higher than that in Pgenesil-1-Stat5A1 group (1.32±0.19 g and 256±10 mm 3 , respectively) (p < 0.01) (Fig. 4B) . The inhibitory rate was 57.7%.
To confirm that the inhibition of xenograft growth is due to the induction of apoptosis by Stat5 knockdown, we examined the apoptosis of SMMC7721 cells isolated from different xenografts. Flow cytometry analysis showed that the apoptosis rate in Pgenesil-1-Stat5A1 group (21.35±3.69%) was significantly higher than in the control NS group (3.56±1.12%) and Pgenesil-1-HK group (3.81±3.05%) (p < 0.05, Fig. 5 ). As expected, Western blot analysis demonstrated that Stat5 protein expression was significantly lower in xenografts derived from Pgenesil-1-Stat5A1 group than in xenografts derived from control NS group and Pgenesil-1-HK group (Fig. 6 ). Taken together, these in vivo data complement the in vitro data shown above and support that Stat5 knockdown induces the apoptosis of SMMC7721 cells to inhibit the tumorigenesis.
Discussion
Previous studies have shown the constitutive activation of Stat5 in a wide variety of human cancer cell lines and primary tumors, including both blood malignancies such as leukemia, lymphomas, and multiple myeloma, and solid tissues tumor such as head and neck, breast, and prostate cancers [9] [10] [11] . However, up to date, no published studies have investigated the expression and role of Stat5 in human hepatocellular carcinoma. In the present study, we reported for the first time that Stat5 was expressed at high level in SMMC7721 human hepatocellular carcinoma cell line. Thus we speculate that Stat5 may play oncogenic role in human hepatocellular carcinoma.
To elucidate the role of Stat5 in human hepatocellular carcinoma, we employed the loss of function approach to knockdown Stat5 in SMMC7721 cells. We designed and synthesized three shRNA sequences targeting the shared region of both Stat5a and Stat5b genes. Further analysis showed that Pgenesil-1-Stat5A1 shRNA exhibited the strongest effect in silencing Stat5 expression in these cells. Thus this vector was selected to deplete Stat5 in SMMC7721 cells for the analysis of the in vitro and in vivo significance of Stat5 knockdown. Our results demonstrate that Stat5 shRNA induced the apoptosis and inhibited the growth of SMCC7721 cells and the derived xenograft in vitro and in vivo. These results are consistent with a recent study reporting that siRNA-mediated Stat3 knockdown inhibited breast tumor growth and metastasis in mice [12] .
Stat5 is represented by two highly homologous genes encoding Stat5a and Stat5b, which are activated in response to a variety of cytokines and growth factors, as well as by oncogenic tyrosine kinases such as Bcr-Abl. Gene-disruption experiments have revealed that Stat5a and Stat5b are not functionally redundant [13] . Further studies are necessary to investigate whether the Stat5a and Stat5b two isoforms have similar or different function in regulating hepatocelluar carcinoma and apoptosis.
Stat5 is known to regulate the expression of a diversity of apoptosis related proteins such as XIAP and Bcl-xL, and activated Stat5 conferred resistance to apoptosis in Bcr-Abl-positive CML cells partially by upregulating Bcl-xL [14, 15] . Another antiapoptotic protein Mcl-1 was shown to be regulated by Stat5 in CML cells and Mcl-1 contributed to Stat-dependent delayed apoptosis in human neutrophils [16] . Survivin, a target gene of Stat5, was highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters [17] . Based on these data, we speculate that Stat5 may enhance the expression of anti-apoptosis proteins such as Bcl-xL or survivin which act as downstream effectors to promote the survival of hepatocellular carcinoma cells.
On the other hand, Stat5b activation has been shown to promote hepatocellular carcinoma aggressiveness through the induction of epithelial-mesenchymal transition, an important aspect of tumor metastasis [18] . However, it remains unclear whether the activation of Stat5 is a primary event in the development of liver cancer or the result of malignant transformation. Interestingly, recent data suggest that in the liver, growth hormone (GH) binds its cognate receptor (GHR) to active JAK2/STAT5 signaling [19] . Further studies are necessary to characterize the molecular mechanisms underlying constitutive activation of STAT5 in human hepatocellular carcinoma cells.
In summary, our findings provide the first evidence for the oncogenic role of Stat5 in hepatocellular carcinoma and suggest that Stat5 shRNA holds promise as a novel gene therapy vector for hepatocellular carcinoma.
